Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents

Clicks: 260
ID: 272363
2016
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
SVR12 rates for sofosbuvir-based DAA regimens in HCV-MCS were 83%, significantly higher than historical controls treated with pegylated interferon and ribavirin; patients with glomerulonephritis experienced improvement in renal function, including those not concomitantly treated with immunosuppressi …
Reference Key
me2016hepatologytreatment Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Sise ME;Bloom AK;Wisocky J;Lin MV;Gustafson JL;Lundquist AL;Steele D;Thiim M;Williams WW;Hashemi N;Kim AY;Thadhani R;Chung RT;;
Journal Hepatology (Baltimore, Md.)
Year 2016
DOI DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/26474537
Keywords
hepatitis c National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't adult female male N.I.H. Extramural aged middle aged Retrospective Studies antiviral agents / therapeutic use* ribavirin / therapeutic use* chronic / drug therapy* interferon-alpha / therapeutic use* clinical study chronic / complications* sofosbuvir / therapeutic use* pmid:26474537 pmc4718772 doi:10.1002/hep.28297 meghan e sise allyson k bloom raymond t chung cryoglobulinemia / drug therapy* cryoglobulinemia / virology*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.